4 курс / Акушерство и гинекология / Журавлева_Е_В_Патогенетическая_профилактика_повторных_преэклампсий

miscarriage and deep vein thrombosis // Am J Reprod Immunol. 2008

Nov;60(5):426-31.

[64]Cunningham FG, Lindheimer MD. Hypertension in pregnancy. New England Journal of Medicine 1992 Apr 2;326(14):927-32.

[65]D`Anna R, Baviera G, Corrado F, Giordano D, De Vivo A, Nicocia G, et al. Adiponectin and insulin resistence in early-and late onset preeclampsia. Br J Obset Gynaecol 2006: 113:1264-1269

[66]De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications // Haematologica. 2002 Oct;87(10):1095-108

[67]de Vries Jlp, Dekker GA, Huijgens PC, et al. Hyperhomcoysteinaemia and protein S deficiency in complicated pregnancies. Br J Obstet Gynaecol.1997;104: 1248-1254.

[68]Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies // J Thromb Haemost. 2005 Feb;3(2):292-9.

[69]Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies // J Thromb Haemost. 2005 Feb;3(2):292-9. (85)

[70]Di Simone N, Meroni PL et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta-2-glycoprotein I. Arthritis Rheum. 2000; 43 (1): 140-150

[71]Di Simone N, Meroni PL, de Papa N et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I // Arthritis Rheum. 2000 Jan;43(1):140-50.

141

[72]Dolitzky M, Inbal A, Brenner B et al. A randomized study of thromboprophilaxis in women with unexplained consecutive recurrent miscarriages. Fertil.Steril. 2006; 86: 362

[73]Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss //Clin Chem. 2003 Jul;49(7):1081-6.

[74]Duckitt K, Harrington D. Risk factors foe preeclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330(7491):565

[75]Eichinger S. Are B vitamins a risk factor for venous thromboembolism? Yes. //J Thromb Haemost. 2006 Feb;4(2):307-8.

[76]Eichinger S. D-dimer testing in pregnancy. // Semin Vasc Med. 2005 Nov;5(4):375-8."

[77]Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant // Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002859.

[78]Fabbro D, D'Elia AV, Spizzo R et al. Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia // Gynecol Obstet Invest. 2003;56(1):17-22."

[79]Fitzpatrick LA, Good A. Micronized progesterone: clinical indications and comparison with current treatments // Fertil Steril. 1999 Sep;72(3):389-97."

[80]Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome // Lupus. 2008 Oct;17(10):872-7."

142

[81]Frenkel E.P., Bick R.L. Prothrombin G20210 gene mutation, Heparin cofactor II defects, primary thrombocytopenia, and thrombohemorrhagic manifestations.// Seminars in thrombosis and hemostasis, Porto, 2000

[82]Gando S, Nakanishi Y, Tedo I: Cytokines and plasminogen activator ingibitor-1 in posttrauma disseminated intravascular coagulation: Relationship to multiple organ dysfunction. Crit Care Med 23:1834, 1995

[83]Germain SJ, Sacks GP et al. Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiothrophoblastmicroparticles. J. Immunol. 2007; 178: 5949-56

[84]Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy // Chest. 2001;119: 122S-131S."

[85]Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest.2003; 112(11): p 1644-1654

[86]Glueck CJ, Kupferminc MJ, Fontaine RN, Wang P, Weksler BB, Eldor A. Genetic hypofibrinolysis in complicated pregnancies // Ostetric Gynecol.2001;97: 44-48.

[87]Glueck CJ, Kupferninc NJ et al. Genetic hypofibrinolisis in complicated pregnancies. Obstet. Gynecol. 2001 Jan; 97 (1): 44-8

[88]Goddijn-Wessel TA, Wouters MG, van der Molen EF, et al. Hyperhomocysteinemia: a risk factor for placental abruption or infarction // Eur J Ostet Gynecol Reprod Biol. 1996;66: 23-29.

[89]Govindaiah V, Naushad SM, Prabhakara K et al. Association of parental hyperhomocysteinemia and C677T Methylene tetrahydrofolate reductase (MTHFR) polymorphism with recurrent pregnancy loss // Clin Biochem. 2009 Mar;42(4-5):380-6."

143

[90]Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy // Blood. 2005 Jul 15;106(2):401-7."

[91]Greet IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review. Blood 2005; 106:401-7

[92]Gris JC, Mercier E et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103 (10): 3695-3699

[93]Gris JC, Mercier E, Quéré I et al. Low-molecular-weight heparin versus lowdose aspirin in women with one fetal loss and a constitutional thrombophilic disorder // Blood. 2004 May 15;103(10):3695-9.

[94]Gris JC, Mercier E, Quéré I et al. Low-molecular-weight heparin versus lowdose aspirin in women with one fetal loss and a constitutional thrombophilic disorder// Blood. 2004 May 15;103(10):3695-9.

[95]Gris JC, Neveu S, Tailand ML, Courtieu C, Mares P, Schved JF. Use of a lowmolecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity // Thromb Haemost. 1995;73: 362-367."

[96]Grosser O., Fruhentwicklung, Eihautbinbung and Placentation des Menschen un der Saugetiere. Munchen: Verlaf von J.F. Bergmann. 1927:74-174

[97]Harkskamp R, Zeeman G. Preeclampsia: At Risk for Remote Cardiovascular Disease. The American Journal of the Medical Sciences 2007. 334(4): 291-295.

[98]Harrison L., Johnson M., Massicotte M.P., Crowther M., Moffat K., Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. // Ann. Intern Med., 1997; 126: 133-136

144

[99]Hills FA, Abrahams VM, González-Timón B et al. Heparin prevents programmed cell death in human trophoblast // Mol Hum Reprod.2006 Apr;12(4):237-43."

[100]Holers VM, Girardi G et al. Complement C3 activation is required for antiphospholipid antibodyinduced fetal loss. J. Exp. Med. 2002; 195(2): 211-220

[101]Hsu CD, Witter FR. Urogenital infection in preeclampsia. Int J Gynaecol Obstet 1995; 49:271-5

[102]Huang SJ, Schatz F et al. Regulation of chemokine production in response to pro-inflammatory cytokines in first trimester decidual cells. J. Reprod.Immunol. 2006; 72 (1-2): 60-73

[103]Izci B, Riha RL, Martin SE, Vennelle M, Liston WA, Dundas KS, et al. The upper airway in pregnancy and preeclampsia. Am J Respir Crit Care Med 2003; 167:137-140

[104]James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes // Obstet Gynecol Surv. 2008 Jan;63(1):49-57.

[105]James RM, Gammill H. Insulin resistance in preeclampsia. Hypertension 2006; 47: 341-342

[106]Jensen JT, Burke AE, Barnhart KT et al. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis // Contraception. 2008 Dec;78(6):451-8. (131)"

[107]Jespersen J. Plasma resistance to activated protein C: an important link, between venous thromboembolism and combined oral contraceptives – a short review. Eur. J. Contracept.Reprod. Health Care 1996; 1:3-11

[108]Jespersen J. Plasma resistance to activated protein C: an important link, between venous thromboembolism and combined oral contraceptives – a short review. Eur. J. Contracept.Reprod. Health Care 1996; 1:3-11

145

[114]Kaaroud H, Beji S, Guermazi S et al. Bleeding and thrombosis in a patient with econdary antiphospholipid syndrome // Saudi J Kidney Dis Transpl. 2008 Mar;19(2):227-31.

[115]Kelly PJ, Rosand J, Kistler JP et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a meta-analysis // Neurology. 2002 Aug 27;59(4):529-36.

[116]Khamashta MA. Hughes syndrome. Antiphospholipid syndrome// Second edition. – Springer. London, 2006. – 598 p.

[117]Kovac M, Mitic G et al. Thrombophilia in women with pregnancy-associated complications: fetal loss and pregnancy-related venous thromboembolism\\Gynecol.Obstet. Invest. 2010; 69(4): 233-8

[118]Kristen Duckitt ea al. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ Mar. 12, 2005; 330:565

[119]Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome //Curr Rheumatol Rep. 2010 Feb;12(1):53-7. (140)

[120]Kupferminc MJ, Fait G et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20(1): 35-44

146

[121]Kupferminc MJ, Fait G, Many A, et al. A low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia // Hypertens Preg. 2001;20: 35-44.

[122]Kupferminc MJ, Peaceman AM, Aderka D, Wallach D, Socol ML. Solube tumor necrosis factor and interleukin-6 in patient with severe preeclampsia. Obstet Gynecol 1998; 179:80-86

[123]Kupferminc MJ. Thrombophilia and pregnancy. Reprod.Biol.Endocrinol. 2003; 1: 111

[124]Laivuori H, Kaaja R, Koistinen H, et al. Leptin during and after preeclamptic or normal pregnancy: its relation to serum insulin and insulin sensitivity. Metab: Clin Exp 2000;49:259-63

[125]Laivuory H, Kaaja R, Turpeinen U, Viinikka L, Ylikorkala O. Plasma homocysteine levels elevated and inversely related to insulin sensitivity in preeclampsia. Obstet Gynecol 1999; 93: 489-493

[126]Lanir N, Aharon A, Brenner B. Haemostaticmachanisms in human placenta. Best Pract. Res. Clin.Haematol. 2003; 16(2): 183-195

[127]Laude I, Rongieres-Bertrand C, Boyer-Neumann C, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight // Thromb Haemost. 2001;85: 18-21.

[128]Lepercq J, Conard J, Borel-Derlon A et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies // BJOG. 2001 Nov;108(11):1134-40.

[129]Levi M, van der Poll T. Two-way interactions between inflammation and coagulation. Trends. Cardiovase Med. 2005; 15 (7): 254-259

[130]Lim W. Antiphospholipid antibody syndrome // Hematology Am Soc Hematol Educ Program. 2009:233-9.

147

[131]Lockwood CJ, Huang SJ et al. Decidual Haemostasis, Inflammation and Angiogenesis in Preeclampsia. Seminars in Thromb.Hemost. Vol 37, number 2, 2011: 158-163

[132]Lockwood CJ, Toti P et al. Thrombin regulates soluble fms-like tyrosine kinase-1 (s-Flt-1) expression in first trimester deciduas: implications for preeclampsia. Am. J. Pathol. 2007; 170(4): 1398-1405

[133]Lopez-Jaramillo P., Casas J.P., Serrano N. Preeclampsia: from epidemiological observations to molecular mechanisms // Braz. J. of Med. And Biol. Research. -2001; 34: 1227-1235

[134]Lyall Fiona, Belfort Michael, editors. Preeclampsia . Etiology and clinical practice. Cambridge, UK: Cambridge University Press; 2007.

[135]Mak A, Cheung MW, Cheak AA, Ho RC. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression // Rheumatology. 2010 Feb;49(2):281-8. (154)"

[136]Marlar RA, Husain S. The enigmas of the lupus anticoagulant: mechanisms, diagnosis, and management // Curr Rheumatol Rep. 2008 Jan;10(1):74-80

[137]Maternal mortality--United States, 1982-1996. Morbidity and Mortality Weekly Report (MMWR) 1998 Sep 4;47(34):705-7.

[138]McCully KS. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation // Ann Clin Lab Sci. 2009 Summer;39(3):219-32. (160)"

[139]Mehdi AA, Uthman I, Khamashta M. Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future // Eur J Clin Invest. 2010 May;40(5):451-64. (161)"

148

[140]Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 2006; 91:2906-12

[141]Mello G, Parretti E, Fatini C et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women // Hypertension. 2005 Jan;45(1):86 91

[142]Mello G., Parretti E. et al; Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005; 46: 1270-1274.

[143]Meltzer ME, Doggen CJ, de Groot PG et al. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis // Semin Thromb Hemost. 2009 Jul;35(5):468-77.

[144]Meroni PL, Rashi E et al. Endotelial cell activation by antiphospholipid antibodies. Clin.Immunol., 2004; 112 (2): 169-74

[145]Messerli M, May K et al. Feto-maternal intervactions in pregnancies: placental microparticles activate peripheral blood monocytes. Placenta 2010; 31 (2): 106-112

[146]Meziani F, Tesse A et al. Shed membrane particles from preeclamptic women generate vascular wall inflammation and blunt vascular contractility. Am. J. Pathol. 2006; 169 (4): 1473-1483

[147]Mittendorf R, Lain KY, Williams MA, Walker CK. Preeclampsia. A nested, case-control study of risk factors and their interactions. J Reprod Med 1996; 41:491-6

[148]Moffett A, Loce C. Immunology of placentation in eutherian mammals. Na Rev Immonol 2006; 6: 584-594

149

[149]Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172

[150]Mousa SA. Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links // Semin Thromb Hemost. 2007 Jul;33(5):524-33. (166)

[151]National Institute for Clinical Excellence. Why Women die. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom, 1997-1999. London:RCOG Press; 2001

[152]Nelen WLDM, Blom HJ, Steegers EAP, den Heijer M, Eskes TKAM. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis // Fertil Steril. 2000;74: 1196-1199.

[153]Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of pre-eclampsia: a hypothesis and its implications. Am J Obstet Gynecol 1996; 175: 1365-1370

[154]NICE NNational Institute for Health and Clinical Excellence clinical guideline 107 Hypertension in pregnancy: the management of hypertension disorders during pregnancy. 2010

[155]Nielsen CM, Hansen K, Andersen HMK, Gerstoft J, Vestergaard BF. A biotin-avidin-amplified inhibition enzyme immunoassay for detection of CMV antibodies in human serum. J Virol Methods 1987;16:195-208

[156]Nizzi FA Jr, Kaplan HS. Protein C and S deficiency // Semin Thromb Hemost.1999;25(3):265-72.

[157]Noble LS, Kutteh WH, Lashey N et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin // Fertil Steril. 2005 Mar;83(3):684-90.

150